Molecular Partners AG ADR (MOLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has a cash flow conversion efficiency ratio of -0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.67 Million) by net assets ($80.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MOLN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Molecular Partners AG ADR - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Molecular Partners AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Molecular Partners AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Partners AG ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
0.070x |
|
Sabina Public Company Limited
BK:SABINA
|
0.101x |
|
Asia Tech Image
TWO:4974
|
0.004x |
|
Boa Safra Sementes S.A
SA:SOJA3
|
-0.074x |
|
Gobarto S.A.
WAR:GOB
|
0.057x |
|
Zig Sheng Industrial Co Ltd
TW:1455
|
0.090x |
|
Bonterra Energy Corp
TO:BNE
|
0.022x |
|
Lin Horn Technology Co Ltd
TWO:5464
|
0.058x |
Annual Cash Flow Conversion Efficiency for Molecular Partners AG ADR (2013–2025)
The table below shows the annual cash flow conversion efficiency of Molecular Partners AG ADR from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Molecular Partners AG ADR (MOLN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.33 Million | $-51.26 Million | -0.638x | -52.53% |
| 2024-12-31 | $141.64 Million | $-59.25 Million | -0.418x | -25.08% |
| 2023-12-31 | $176.43 Million | $-59.01 Million | -0.334x | -166.33% |
| 2022-12-31 | $235.17 Million | $118.57 Million | 0.504x | +159.47% |
| 2021-12-31 | $107.29 Million | $-90.95 Million | -0.848x | -213.61% |
| 2020-12-31 | $107.22 Million | $-28.98 Million | -0.270x | -1130.82% |
| 2019-12-31 | $54.14 Million | $-1.19 Million | -0.022x | +95.26% |
| 2018-12-31 | $91.70 Million | $-42.47 Million | -0.463x | -35.09% |
| 2017-12-31 | $116.73 Million | $-40.02 Million | -0.343x | -31.60% |
| 2016-12-31 | $135.79 Million | $-35.38 Million | -0.261x | -249.27% |
| 2015-12-31 | $151.79 Million | $26.50 Million | 0.175x | +328.68% |
| 2014-12-31 | $148.48 Million | $-11.33 Million | -0.076x | +72.91% |
| 2013-12-31 | $48.32 Million | $-13.61 Million | -0.282x | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more